Thromb Haemost 2013; 110(01): 01
DOI: 10.1160/TH13-05-0357
T&H Insights
Schattauer GmbH

Procoagulants for management of bleeding with the new oral anticoagulants

John W. Eikelboom
1   Department of Medicine, McMaster University, Hamilton, Ontario, Canada
,
Jeffrey I. Weitz
1   Department of Medicine, McMaster University, Hamilton, Ontario, Canada
2   Department of Biochemistry and Biomedical Sciences, McMaster University and Thrombosis & Atherosclerosis Research Institute, Hamilton, Ontario, Canada
› Author Affiliations
Further Information

Publication History

Received: 02 May 2013

Accepted: 02 May 2013

Publication Date:
30 November 2017 (online)

Insight on: Perzborn et al. Thromb Haemost 2013; 110: 162-172.

 
  • References

  • 1 Perzborn E, Gruber A, Tinel H. et al. Reversal of rivaroxaban anticoagulation by haemostatic agents in rats and primates. Thromb Haemost 2013; 110: 162-172.
  • 2 Eerenberg ES, Kamphuisen PW, Sijpkens MK. et al. Reversal of rivaroxaban and dabigatran by pro thrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011; 124: 1573-1579.
  • 3 Godier A, Miclot A, Le Bonniec B, Durand M. et al. Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model. Anesthesiology 2012; 116: 94-102.
  • 4 Zhou W, Zorn M, Nawroth P. et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with rivaroxaban. Stroke 2013; 44: 771-778.
  • 5 Southworth MR, Reichman ME, Unger EF. Dabi gatran and postmarketing reports of bleeding. N Engl J Med 2013; 368: 1272-1274.
  • 6 Weitz JI, Quinlan DJ, Eikelboom JW. Peripro cedural management and approach to bleeding in patients taking dabigatran. Circulation 2012; 126: 2428-2432.